SELLAS Life Sciences (SLS) Long-Term Debt Issuances (2016 - 2017)
SELLAS Life Sciences (SLS) reported Long-Term Debt Issuances of -$4.4 million for Q2 2017, down 118.82% year-over-year from $23.6 million in Q2 2016, and down 200.0% on a QoQ basis from $4.4 million in Q1 2017.
SELLAS Life Sciences (SLS) has 2 years of Long-Term Debt Issuances data on file, last reported at -$4.4 million in Q2 2017.
- Quarterly Long-Term Debt Issuances fell 118.82% year-over-year to -$4.4 million in Q2 2017, while the trailing twelve-month figure through Sep 2017 was -$8.6 million (down 136.55% YoY) and the FY2016 annual result came in at $15.0 million, changed N/A from the prior year.
- Long-Term Debt Issuances declined to -$4.4 million in Q2 2017 per SLS's latest filing, from $4.4 million in the prior quarter.
- Across five years, Long-Term Debt Issuances topped out at $23.6 million in Q2 2016 and bottomed at -$8.6 million in Q4 2016.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 2.73 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | SELLAS Life Sciences | 1.61 Bn | 1.61 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2017 | -4.45 Mn |
| Jun 30, 2017 | -4.45 Mn |
| Mar 31, 2017 | 4.45 Mn |
| Mar 31, 2017 | 4.45 Mn |
| Dec 31, 2016 | -8.64 Mn |
| Dec 31, 2016 | -8.64 Mn |
| Jun 30, 2016 | 23.64 Mn |
| Jun 30, 2016 | 23.64 Mn |